It was a result that exceeded my expectations (which, admittedly, were not exactly sanguine) by a considerable way.
The real surprise to me was the leap in the operating margin, during a period which would certainly have been tough, operationally and in terms of costs, given WA was still in self-isolation from the rest of the world.
I fully expected the margin to remain under pressure, for at least the DH2021 and even the current half, too, before MND would be in a position to re-price contracts to recoup the input cost inflation it would certainly be experiencing.
But I was wrong; they have already started to achieve it in the previous half-year, which is quite some feat, given the extraneous circumstances.
Valuation-wise, whenever I've owned MND, it has been predicated on the business generating $150m EBIT at some point during the cyclical upswing in its business.
(It is unlikely to require getting EBIT margin back to the 9% level seen during the last commodity boom; a mere 6% EBIT Margin on $2.5bn of Revenue will do it... and there certainly is going to be enough work going around over the next 3 years for MND to be doing $2.5bn worth of work... its currently doing an annualised run rate in excess of $2.0bn @4.6% EBIT margin, so its already within reach of the $100m EBIT mark, and the cyclical upswing has only just begun.)
Capitalising that $150m EBIT at a conservative 8x EV/EBIT (it averaged around 9.5x during the previous cyclical high period between 2010-2013), yields an EV of $1.2bn.
Add to that the $150m-odd in Net Cash and you get an Equity Value of ~$1.35bn, or around $14.20 per share, so 25% potential investment return, with a high level of conviction
From my vantage point, which sees a challenging investment environment in which extraneous risks are elevated, 25% upside with high conviction is an attractive risk-adjusted investment return.
Can't see the broader equity market putting on another 25% over the next 12 to 18 months.
.
- Forums
- ASX - By Stock
- Ann: Monadelphous Reports 2022 Half Year Results
It was a result that exceeded my expectations (which,...
Featured News
Add MND (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.42 |
Change
-0.010(0.08%) |
Mkt cap ! $1.222B |
Open | High | Low | Value | Volume |
$12.45 | $12.50 | $12.30 | $2.678M | 215.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 516 | $12.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.45 | 647 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3081 | 12.300 |
2 | 3700 | 12.250 |
1 | 2000 | 12.210 |
1 | 400 | 12.200 |
1 | 2000 | 12.170 |
Price($) | Vol. | No. |
---|---|---|
12.500 | 29 | 1 |
12.510 | 5000 | 1 |
12.550 | 5000 | 1 |
12.600 | 70 | 1 |
12.700 | 1725 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
MND (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online